{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-030670","form_type":"8-K","ticker":"CVGI","cik":"0001290900","company_name":"Commercial Vehicle Group, Inc.","filed_at":"2026-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.099399+00:00","generated_at":"2026-05-14T23:15:56.474597+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"CVG Q1 revenue up 1% to $171.5M; EPS $0.03; adjusted EBITDA $4.8M, down 17%","bullets":["Revenue $171.5M (+1% YoY); GAAP net income $0.9M ($0.03 diluted EPS) vs loss of $3.1M in Q1 2025.","Adjusted net loss $3.4M ($0.10 per share) widened from adjusted loss $2.6M ($0.08) in prior year.","Adjusted EBITDA $4.8M, down 17% YoY; margin 2.8% vs 3.4%.","Completed sale-leaseback of Vonore, TN facility; reduced debt $12.8M since year-end 2025.","Reaffirmed FY2026 guidance: net sales $660-700M, adjusted EBITDA $24-30M, positive FCF."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-030670","json":"https://secwatch.observer/filing/0001628280-26-030670.json","markdown":"https://secwatch.observer/filing/0001628280-26-030670.md","text":"https://secwatch.observer/filing/0001628280-26-030670.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1290900/000162828026030670/0001628280-26-030670-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1290900/000162828026030670/cvgi-20260505.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T23:15:56.474597+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"db96f439e4c9d7d9a1a16c0dbf61e2adc81e7b80","claim":"Commercial Vehicle Group, Inc. reported first quarter ended March 31, 2026 results: revenue $171.5 million, net income $0.9 million, EPS $0.03 per diluted share. Guidance reaffirmed.","evidence_excerpt":"• Revenues of $171.5 million, up 1.0%, primarily driven by 14% growth in our Global Electrical Systems segment. • Operating income of $14.7 million, which included $14.0 million gain on sale of assets, was up $13.3 million, compared to $1.4 million. Adjusted operating income of $2.0 million, relatively flat compared to $2.1 million. • Net income from continuing operations of $0.9 million, or $0.03 per diluted share and adjusted net loss of $3.4 million, or $(0.10) per diluted share, compared to net loss from continuing operations of $3.1 million, or $(0.09) per diluted share and adjusted net loss of $2.6 million, or $(0.08) per diluted share.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1290900/000162828026030670/0001628280-26-030670-index.htm","confidence":0.95}],"comparable_filings":[{"accession":"0001493152-26-026770","ticker":"POLA","company_name":"Polar Power, Inc.","filed_at":"2026-06-02T12:30:26+00:00","headline":"Polar Power Q1 net loss narrows 86% to $178K; gross margin expands to 65.7%","event_type":"earnings","sec_items":["2.02","7.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 7.01, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-026770","json":"https://secwatch.observer/filing/0001493152-26-026770.json","markdown":"https://secwatch.observer/filing/0001493152-26-026770.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1622345/000149315226026770/0001493152-26-026770-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1622345/000149315226026770/form8-k.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"• Revenues of $171.5 million, up 1.0%, primarily driven by 14% growth in our Global Electrical Systems segment. • Operating income of $14.7 million, which included $14.0 million gain on sale of assets, was up $13.3 million, compared to $1.4 million. Adjusted operating income of $2.0 million, relatively flat compared to $2.1 million. • Net income from continuing operations of $0.9 million, or $0.03 per diluted share and adjusted net loss of $3.4 million, or $(0.10) per diluted share, compared to net loss from continuing operations of $3.1 million, or $(0.09) per diluted share and adjusted net loss of $2.6 million, or $(0.08) per diluted share.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1290900/000162828026030670/0001628280-26-030670-index.htm","comparable_excerpt":"Q1 2026 Q1 2025 Y/Y +/(-) Change Net sales $ 1,728 $ 1,723 — Gross profit $ 1,135 $ 320 255 % Gross margin 65.7 % 18.6 % 47.1 pts Total operating expenses $ 1,111 $ 1,421 22 % Income (loss) from operations $ 24 $ (1,101 ) 102 % Net loss $ (178 ) $ (1,265 ) 86 % Net loss per share $ (0.05 ) $ (0.50 ) 90 %","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1622345/000149315226026770/0001493152-26-026770-index.htm"}},{"accession":"0001104659-26-058204","ticker":"EXPI","company_name":"eXp World Holdings, Inc.","filed_at":"2026-05-11T23:59:59+00:00","headline":"eXp World Holdings Q1 revenue $1.0B (+5% YoY), net loss narrows to $(5.1M), Adj. EBITDA $4.1M (+88%)","event_type":"earnings","sec_items":["2.02","7.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 7.01, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-058204","json":"https://secwatch.observer/filing/0001104659-26-058204.json","markdown":"https://secwatch.observer/filing/0001104659-26-058204.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1495932/000110465926058204/0001104659-26-058204-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1495932/000110465926058204/agnt-20260511x8k.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"• Revenues of $171.5 million, up 1.0%, primarily driven by 14% growth in our Global Electrical Systems segment. • Operating income of $14.7 million, which included $14.0 million gain on sale of assets, was up $13.3 million, compared to $1.4 million. Adjusted operating income of $2.0 million, relatively flat compared to $2.1 million. • Net income from continuing operations of $0.9 million, or $0.03 per diluted share and adjusted net loss of $3.4 million, or $(0.10) per diluted share, compared to net loss from continuing operations of $3.1 million, or $(0.09) per diluted share and adjusted net loss of $2.6 million, or $(0.08) per diluted share.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1290900/000162828026030670/0001628280-26-030670-index.htm","comparable_excerpt":"the company's scale and our focus on operational efficiency across eXp World Holdings,” said Jesse Hill, Chief Financial Officer of eXp World Holdings. “We generated revenue of $1.0 billion and Adjusted EBITDA of $4.1 million, an 88% improvement that further strengthened our financial position. More recently, we executed the strategic NextHome acquisition using cash","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1495932/000110465926058204/0001104659-26-058204-index.htm"}},{"accession":"0001544206-26-000032","ticker":"CGBD","company_name":"Carlyle Secured Lending, Inc.","filed_at":"2026-05-11T23:59:59+00:00","headline":"Carlyle Secured Lending Q1 NII $0.36/sh; NAV down 2.3% to $15.89; declares $0.35 dividend","event_type":"earnings","sec_items":["2.02","7.01","9.01"],"materiality_score":0.55,"calibrated_materiality_score":0.55,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 7.01, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001544206-26-000032","json":"https://secwatch.observer/filing/0001544206-26-000032.json","markdown":"https://secwatch.observer/filing/0001544206-26-000032.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1544206/000154420626000032/0001544206-26-000032-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1544206/000154420626000032/csl-20260511.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"• Revenues of $171.5 million, up 1.0%, primarily driven by 14% growth in our Global Electrical Systems segment. • Operating income of $14.7 million, which included $14.0 million gain on sale of assets, was up $13.3 million, compared to $1.4 million. Adjusted operating income of $2.0 million, relatively flat compared to $2.1 million. • Net income from continuing operations of $0.9 million, or $0.03 per diluted share and adjusted net loss of $3.4 million, or $(0.10) per diluted share, compared to net loss from continuing operations of $3.1 million, or $(0.09) per diluted share and adjusted net loss of $2.6 million, or $(0.08) per diluted share.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1290900/000162828026030670/0001628280-26-030670-index.htm","comparable_excerpt":"For the first quarter of 2026, we reported $0.36 per common share of Net Investment Income and Adjusted Net Investment Income, a non-GAAP financial measure described below.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1544206/000154420626000032/0001544206-26-000032-index.htm"}},{"accession":"0001178913-26-002455","ticker":"ENTXW","company_name":"Entera Bio Ltd.","filed_at":"2026-05-08T23:59:59+00:00","headline":"Entera Bio Q1 net loss $3.5M; cash $20.4M; EB613 Phase 3 protocol submitted to FDA","event_type":"earnings","sec_items":["2.02","7.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 7.01, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-26-002455","json":"https://secwatch.observer/filing/0001178913-26-002455.json","markdown":"https://secwatch.observer/filing/0001178913-26-002455.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1638097/000117891326002455/0001178913-26-002455-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1638097/000117891326002455/zk2635218.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"• Revenues of $171.5 million, up 1.0%, primarily driven by 14% growth in our Global Electrical Systems segment. • Operating income of $14.7 million, which included $14.0 million gain on sale of assets, was up $13.3 million, compared to $1.4 million. Adjusted operating income of $2.0 million, relatively flat compared to $2.1 million. • Net income from continuing operations of $0.9 million, or $0.03 per diluted share and adjusted net loss of $3.4 million, or $(0.10) per diluted share, compared to net loss from continuing operations of $3.1 million, or $(0.09) per diluted share and adjusted net loss of $2.6 million, or $(0.08) per diluted share.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1290900/000162828026030670/0001628280-26-030670-index.htm","comparable_excerpt":"Entera Bio Ltd. (NASDAQ: ENTX) (\"Entera\" or the \"Company\"), a leader in the development of oral peptides, today reported financial results and key business updates for the quarter ended March 31, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1638097/000117891326002455/0001178913-26-002455-index.htm"}},{"accession":"0001193125-26-213371","ticker":"RPC","company_name":"Ridgepost Capital, Inc.","filed_at":"2026-05-08T23:59:59+00:00","headline":"Ridgepost Capital reports record AUM of $31B in Q1 2026, up 18% YoY","event_type":"earnings","sec_items":["2.02","7.01","8.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 7.01, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-213371","json":"https://secwatch.observer/filing/0001193125-26-213371.json","markdown":"https://secwatch.observer/filing/0001193125-26-213371.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1841968/000119312526213371/0001193125-26-213371-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1841968/000119312526213371/rpc-20260507.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"• Revenues of $171.5 million, up 1.0%, primarily driven by 14% growth in our Global Electrical Systems segment. • Operating income of $14.7 million, which included $14.0 million gain on sale of assets, was up $13.3 million, compared to $1.4 million. Adjusted operating income of $2.0 million, relatively flat compared to $2.1 million. • Net income from continuing operations of $0.9 million, or $0.03 per diluted share and adjusted net loss of $3.4 million, or $(0.10) per diluted share, compared to net loss from continuing operations of $3.1 million, or $(0.09) per diluted share and adjusted net loss of $2.6 million, or $(0.08) per diluted share.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1290900/000162828026030670/0001628280-26-030670-index.htm","comparable_excerpt":"Ridgepost Capital, Inc (NYSE: RPC), a leading private markets solutions provider, today announced financial results for the first quarter ended March 31, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1841968/000119312526213371/0001193125-26-213371-index.htm"}},{"accession":"0001493152-26-026777","ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2026-06-02T12:40:33+00:00","headline":"INVO Fertility FY2025 revenue $6.84M (+5% YoY); net loss improves to $(5.3)M","event_type":"earnings","sec_items":["2.02","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-026777","json":"https://secwatch.observer/filing/0001493152-26-026777.json","markdown":"https://secwatch.observer/filing/0001493152-26-026777.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1417926/000149315226026777/0001493152-26-026777-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1417926/000149315226026777/form8-k.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"• Revenues of $171.5 million, up 1.0%, primarily driven by 14% growth in our Global Electrical Systems segment. • Operating income of $14.7 million, which included $14.0 million gain on sale of assets, was up $13.3 million, compared to $1.4 million. Adjusted operating income of $2.0 million, relatively flat compared to $2.1 million. • Net income from continuing operations of $0.9 million, or $0.03 per diluted share and adjusted net loss of $3.4 million, or $(0.10) per diluted share, compared to net loss from continuing operations of $3.1 million, or $(0.09) per diluted share and adjusted net loss of $2.6 million, or $(0.08) per diluted share.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1290900/000162828026030670/0001628280-26-030670-index.htm","comparable_excerpt":"and technologies,\ntoday announced fiscal year 2025 financial results. FY2025\nFinancial Highlights (all metrics compared to FY2024 unless otherwise noted) ● Revenue\n was $6,841,250, an increase of 5% compared to $6,532,000. ● Consolidated\n clinic revenue increased 4% to $6,721,057, compared to $6,450,431. ● Revenue\n from all clinics was $8,021,929, including","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315226026777/0001493152-26-026777-index.htm"}},{"accession":"0001193125-26-215679","ticker":"HAIN","company_name":"HAIN CELESTIAL GROUP INC","filed_at":"2026-05-11T23:59:59+00:00","headline":"Hain Celestial reports Q3 FY2026 earnings; detailed figures not included in filing excerpt","event_type":"earnings","sec_items":["2.02","9.01"],"materiality_score":0.5,"calibrated_materiality_score":0.5,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-215679","json":"https://secwatch.observer/filing/0001193125-26-215679.json","markdown":"https://secwatch.observer/filing/0001193125-26-215679.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/910406/000119312526215679/0001193125-26-215679-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/910406/000119312526215679/hain-20260511.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"• Revenues of $171.5 million, up 1.0%, primarily driven by 14% growth in our Global Electrical Systems segment. • Operating income of $14.7 million, which included $14.0 million gain on sale of assets, was up $13.3 million, compared to $1.4 million. Adjusted operating income of $2.0 million, relatively flat compared to $2.1 million. • Net income from continuing operations of $0.9 million, or $0.03 per diluted share and adjusted net loss of $3.4 million, or $(0.10) per diluted share, compared to net loss from continuing operations of $3.1 million, or $(0.09) per diluted share and adjusted net loss of $2.6 million, or $(0.08) per diluted share.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1290900/000162828026030670/0001628280-26-030670-index.htm","comparable_excerpt":"On May 11, 2026, The Hain Celestial Group, Inc. (the “Company”) issued a press release announcing financial results for its third quarter ended March 31, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/910406/000119312526215679/0001193125-26-215679-index.htm"}},{"accession":"0001193125-26-215752","ticker":"HRTX","company_name":"HERON THERAPEUTICS, INC. /DE/","filed_at":"2026-05-11T23:59:59+00:00","headline":"Heron Q1 net revenue $34.7M (-10.8% YoY); Acute Care up 32%; guidance reaffirmed","event_type":"earnings","sec_items":["2.02","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-215752","json":"https://secwatch.observer/filing/0001193125-26-215752.json","markdown":"https://secwatch.observer/filing/0001193125-26-215752.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/818033/000119312526215752/0001193125-26-215752-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/818033/000119312526215752/hrtx-20260511.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"• Revenues of $171.5 million, up 1.0%, primarily driven by 14% growth in our Global Electrical Systems segment. • Operating income of $14.7 million, which included $14.0 million gain on sale of assets, was up $13.3 million, compared to $1.4 million. Adjusted operating income of $2.0 million, relatively flat compared to $2.1 million. • Net income from continuing operations of $0.9 million, or $0.03 per diluted share and adjusted net loss of $3.4 million, or $(0.10) per diluted share, compared to net loss from continuing operations of $3.1 million, or $(0.09) per diluted share and adjusted net loss of $2.6 million, or $(0.08) per diluted share.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1290900/000162828026030670/0001628280-26-030670-index.htm","comparable_excerpt":"Reaffirms Guidance - Q1 2026 net revenue growth year-over year for Acute Care franchise (+32%), including ZYNRELEF ® (+27%) and APONVIE ® (+50%) - Q1 2026 total net revenue of $34.7 million - Reached settlement with Baxter Healthcare Corporation in CINVANTI ® patent litigation - Reaffirmed 2026 full-year guidance of $173–$183 million net revenue; $10–$20 million","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/818033/000119312526215752/0001193125-26-215752-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}